Clinical benefit of paclitaxel/carboplatin plus bevacizumab with zoledronic acid in pulmonary epithelioid hemangioendothelioma complicated by hypertrophic pulmonary osteoarthropathy and cardiac tamponade: a case report.
Saved in:
| Title: | Clinical benefit of paclitaxel/carboplatin plus bevacizumab with zoledronic acid in pulmonary epithelioid hemangioendothelioma complicated by hypertrophic pulmonary osteoarthropathy and cardiac tamponade: a case report. |
|---|---|
| Authors: | Tsuchimochi S; Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Nakajima H; Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.; Department of Experimental Therapeutics, National Cancer Center Hospital East, Kashiwa, Japan.; Department of General Internal Medicine, National Cancer Center Hospital East, Kashiwa, Japan., Hattori Y; Department of Palliative Medicine, National Cancer Center Hospital East, Kashiwa, Japan., Oda S; Department of Diagnostic Radiology, National Cancer Center Hospital East, Kashiwa, Japan., Imada H; Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Japan., Taki T; Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Japan., Matsuoka A; Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Watanabe S; Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Hirota A; Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Shimura M; Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Fukuda M; Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Funasaka C; Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.; Department of Experimental Therapeutics, National Cancer Center Hospital East, Kashiwa, Japan., Harano K; Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.; Department of Experimental Therapeutics, National Cancer Center Hospital East, Kashiwa, Japan., Matsubara N; Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Naito Y; Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.; Department of Experimental Therapeutics, National Cancer Center Hospital East, Kashiwa, Japan.; Department of General Internal Medicine, National Cancer Center Hospital East, Kashiwa, Japan., Hosono A; Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.; Department of Pediatric Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Ishii G; Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Japan., Mukohara T; Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan. |
| Source: | Frontiers in oncology [Front Oncol] 2026 Jun 02; Vol. 16, pp. 1855346. Date of Electronic Publication: 2026 Jun 02 (Print Publication: 2026). |
| Publication Type: | Case Reports; Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2234-943X |
|---|---|
| DOI: | 10.3389/fonc.2026.1855346 |
